iifl-logo-icon 1
IIFL

Invest wise with Expert advice

By continuing, I accept the T&C and agree to receive communication on Whatsapp

  • Open Demat with exclusive Advice & Services
  • Get a dedicated Relationship Manager to help you grow your wealth
  • Exclusive advisory on 20+ trading & wealth-based investment options
  • One tap Investments, Automated trading & much more
  • Minimum 1 lakh margin required
sidebar image

Q3 net profit of Zydus Life soars 26% YoY, as the board plans a ₹600 Crore buyback

10 Feb 2024 , 10:59 PM

Zydus Lifesciences announced on February 9 that its consolidated net profit for the December quarter of the fiscal year 2023–2024 increased by 26% to ₹789.6 Crore.

In the same period last year, the pharmaceutical company declared a profit of ₹622.9 Crore. The company said in an exchange filing that its revenue from operations was ₹4505.2 Crore, 5.8% more than ₹4257.1 Crore in the previous fiscal year.

The board of the business authorised the tender offer repurchase of 57.9 Lakh shares, valued at ₹600 Crore, at a price of ₹1,005 per share.

Earnings before interest, taxes, depreciation, and amortisation (EBITDA) for the Ahmedabad-based company were recorded at ₹1,102 Crore, an increase from ₹956 during the same time last year. The EBITDA margin increased from 22.5 % to 24.4 % in the previous year.

Dr. Sharvil Patel, Managing Director of Zydus Lifesciences Limited, stated, 'We are optimistic about our growth prospects driven by a differentiated portfolio in the US, continued performance of key brands, well supported by a robust execution engine.'

The company released a press release stating that its India and EM& EU formulations divisions drove a 6 % YoY increase in total revenues. The formulations business in India experienced robust double-digit growth due to the introduction of new products and solid volume growth.

For the quarter, the company reported capex (organic) of ₹213.7 Crore. In the October–December quarter, the firm invested ₹314.6 Crore, or 7% of revenues, in research and development (R&D).

US revenue for the same period last year was $192.5 Million, down from $225 Million (quarter over quarter) and $221 Million. The base business's profitability in the United States increased due to consistent volume growth and the introduction of new products throughout the previous year. During the quarter, the company introduced 11 new goods to the US market.

Revenues from emerging markets totaled ₹49.37 Crore, increasing 31% year over year. Eleven % of total sales came from the business. According to the firm, every significant market in Africa and the Asia Pacific area saw strong double-digit growth throughout the quarter.

Revenues of ₹143.1 Crore were recorded by Active Pharmaceutical Ingredients (API), a 24 % year-over-year decline. Three % of total sales came from the business.

For feedback and suggestions, write to us at editorial@iifl.com

Zydus Lifesciences - Wikipedia

Related Tags

  • Q3
  • result
  • Zydus Life
sidebar mobile

BLOGS AND PERSONAL FINANCE

Images
15 Apr 2024   |   12:16 PM
Images
15 Apr 2024   |   10:33 AM
Images
15 Apr 2024   |   09:44 AM
Read More

Most Read News

15 Apr 2024   |   01:53 PM
15 Apr 2024   |   01:52 PM
Read More
Knowledge Centerplus
Logo

Logo IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000

Logo IIFL Securities Support WhatsApp Number
+91 9892691696

Download The App Now

appapp
Knowledge Centerplus

Follow us on

facebooktwitterrssyoutubeinstagramlinkedin

2024, IIFL Securities Ltd. All Rights Reserved

ATTENTION INVESTORS
  • Prevent Unauthorized Transactions in your demat / trading account Update your Mobile Number/ email Id with your stock broker / Depository Participant. Receive information of your transactions directly from Exchanges on your mobile / email at the end of day and alerts on your registered mobile for all debits and other important transactions in your demat account directly from NSDL/ CDSL on the same day." - Issued in the interest of investors.
  • KYC is one time exercise while dealing in securities markets - once KYC is done through a SEBI registered intermediary (broker, DP, Mutual Fund etc.), you need not undergo the same process again when you approach another intermediary.
  • No need to issue cheques by investors while subscribing to IPO. Just write the bank account number and sign in the application form to authorise your bank to make payment in case of allotment. No worries for refund as the money remains in investor's account."

www.indiainfoline.com is part of the IIFL Group, a leading financial services player and a diversified NBFC. The site provides comprehensive and real time information on Indian corporates, sectors, financial markets and economy. On the site we feature industry and political leaders, entrepreneurs, and trend setters. The research, personal finance and market tutorial sections are widely followed by students, academia, corporates and investors among others.

RISK DISCLOSURE ON DERIVATIVES
  • 9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
  • On an average, loss makers registered net trading loss close to Rs. 50,000.
  • Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
  • Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.
Copyright © IIFL Securities Ltd. All rights Reserved.

Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248

plus
We are ISO 27001:2013 Certified.

This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.

closeIcon

Get better recommendations & make better investments

Invest wise with Expert advice

By continuing, I accept the T&C and agree to receive communication on Whatsapp